The Medicinal Metallochemistry of Alzheimer's Disease

Authors: Cherny R.A.; Masters C.L.; Bush A.I.

Source: Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents, Volume 3, Number 1, March 2003 , pp. 9-13(5)

Publisher: Bentham Science Publishers

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The brain is an organ which is at once enriched in transition metals and highly susceptible to oxidative stress. By virtue of its high affinity for copper the Alzheimer's amyloid protein (Abgr) is capable of catalytic generation of neurotoxic H2O2 while its aggregation and deposition are zinc-dependent. These properties are exaggerated by conditions present in the aging brain. Amyloid from human brain specimens can be solubilized by the application of selected Cu / Zn chelators thus demonstrating the role of metals in amyloid architecture. Similarly, the toxicity of the metal / Abgr complex is ameliorated by metal complexing agents. Clioquinol, a bioavailable Cu / Zn chelator has been successfully used to inhibit amyloid deposition in a transgenic animal model for Alzheimer's disease and is presently undergoing human efficacy trials.

Keywords: metallochemistry; alzheimer disease; clioquinol

Language: English

Document Type: Review article

DOI: 10.2174/1568013033358626

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A